Personalized antibiotic dosing could save ICU pneumonia patients

NCT ID NCT04986254

Completed Knowledge-focused Sponsor: The University of Queensland Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study looked at 179 ICU patients with pneumonia to figure out the best doses of common antibiotics. Researchers took blood and lung fluid samples to measure how the drugs move through the body. The goal was to create personalized dosing plans that ensure enough antibiotic reaches the infection site, which could improve treatment and fight drug resistance.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: antibiotics (benzylpenicillin, ceftriaxone, meropenem, piperacillin/tazobactam)
What this could lead to: If successful, this could lead to personalized antibiotic dosing for ICU pneumonia patients, potentially improving cure rates and reducing antibiotic resistance.
What could go wrong: This was a small, early-stage study (179 participants) focused on measuring drug levels, not on patient outcomes. The proposed dosing regimens still need to be tested in larger trials to see if they actually improve survival or recovery.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PNEUMONIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Critical Illness pneumonia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PNEUMONIA

Contacts and locations

Locations

Centre Hospitalier Universitaire de Nimes

Nîmes, France
Chinese University of Hong Kong

Hong Kong, Hong Kong
Royal Brisbane and Women's Hospital

Brisbane, Australia
The Alfred

Melbourne, Australia
University Hospital, Ghent

Ghent, Belgium
University of Malaya

Kuala Lumpur, Malaysia

More trials for these conditions

Other studies related to the condition(s) this trial covers.